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Stem Cell Reports frequently receives manuscripts dealing with the topic of cancer stem cells. Many of the submissions on this topic have
major shortcomings in their content or limits to the conclusions that can be drawn from the results presented. The purpose of this Com-
mentary is to highlight some of the underlying issues so that authors can enhance the strength of their research contributions.
Stem Cell Reports frequently receives manuscripts dealing
with the topic of cancer stem cells. We recognize that this
field is an exciting and highly active area of research with
potentially profound implications for our understanding
of the heterogeneity of malignant cell populations and
their genesis, maintenance, response to treatment, and
continued diversification. From a translational perspective,
the results may also be key to the discovery and testing of
new approaches to prognosis and therapy. We therefore
welcome submissions that provide new insights into the
biology and molecular features of cancer stem cells, as
well as new insights into their regulation. Unfortunately,
we find that many of the submissions on this topic that
we receive have major shortcomings in their content, or
limits to the conclusions that can be drawn from the results
presented. These contrubtions are therefore returned to
authors directly without the delay of a deeper review so
that authors can more quickly have the option to submit
their work to another journal. The purpose of this
Commentary is to highlight some of the underlying issues.
Many of these have been covered in detail in an excellent
recent review of the cancer stem cell field (Clarke, 2019).
Limitations of Surrogate Markers to Identify the
Behavior of Cancer Stem Cells
Weview the concept of a cancer stem cell as a biological one.
Therefore, use of this term requires some form of rigorous
and reproducible experimental measurement of biologi-
cally demonstrated stem cell activity. The term ‘‘cancer
stem cell’’ was originally introduced to recognize the fact
that in most naturally arising cancers, only some of the
cells were found to proliferate and only a subset with
distinct properties were able to sustain the maintenance
of the tumor for an extended period of time. Since current
evidence also indicates that many malignant populations
contain cells with limited proliferative ability, it is impor-
tant to distinguish them experimentally from those with
a proliferative potential more fitting the definition of
cancer stem cells. This has led to the need for measure-
ments that assess cancer cell ‘‘stemness’’ more stringently
by demonstrating that a single cell can produce not only
a primary population with the properties of clinically
accepted features of malignancy but also progeny that
include cells that do the same thing. Evidence of this prop-
erty is now usually reliant on the use of serial transplanta-
tion assays in vivo or serial organoid formation in vitro.
However, even these endpoints have shortcomings, as se-
rial transplants are often detecting clones not seen in the
primary recipient and hence are not formal evidence of
their genesis via a self-renewal division. Expression of a
particular cell surface marker or gene expression pattern,
or expression of intrinsic cellular or molecular features
(e.g., detectability as a side population when labeled with
Hoechst 33342, retention of labels that are lost with repet-
itive cell cycles, or sphere formation in vitro), have not yet
been shown to isolate any malignant cells with the biolog-
ical properties of cancer stem cells, as defined above, at suf-
ficient purity to allow them to serve as direct substitute
measures of such cells. Data reliant exclusively on such
markers or assays have in the past proven to be misleading
about cells with the biological properties of cancer stem
cells.
At the same time, we recognize that experiments that can
be performed in mice or other species can often address
properties of cancer stem cells that are difficult or not yet
possible to obtain from experiments with human cells
because of the inherent limitations of currently available
xenotransplantation approaches or in vitro systems. For
this reason, we welcome studies that make appropriate
use of all such model systems.
Limitations of Established Cancer Cell Lines
Established cell lines have provided many important
insights into cancer biology and relevant pathway pertur-
bations that result from specific mutations or epigenetic
alterations in cells. However, we feel it is important to
recognize that most of the widely available cancer cell lines
in use were derived by explanting patient biopsies into
simple culture systems that employed basal media supple-
mented with serum, unmodified tissue culture plastic as a
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substrate, and dissociation of the original malignant popu-
lation into single cells with trypsin to select for those able
to be continuously passaged and expanded in vitro under
such conditions. It is now clear that very few primary hu-
man malignant cells can survive and proliferate under
such circumstances because they display additional phys-
ical and molecular requirements for growth in vitro. These
may include specific niche factors that may be delivered
through cell-cell or extracellular matrix contact to support
their continued growth in vivo or serial propagation . Thus,
many of the older, established cell lines are poorly repre-
sentative of the malignant cell populations from which
they originated. Moreover, epigenetic and indeed genetic
changes acquired during their adaptation and long-term
propagation in vitro are likely to have contributed to the
acquisition of phenotypes and other properties not rele-
vant to the original malignant cells from which they
derived. For these reasons, studies based on primary tumor
biopsies, early-passage patient-derived xenografts, early-
passage organoids that preserve the in vivo microenviron-
ment, or malignant cells generated de novo directly from
primary sources of normal human cells are anticipated to
yield more convincing and informative data on cancer
stem cell populations and their properties. However, as dis-
cussed below, their heterogeneity and finite availability
also pose recognized challenges.
Limitations Inherent in the Heterogeneity and
Instability of Cancer Cell Populations
Conclusions based on generalizations and untested as-
sumptions about the structure of cell populations within
a tumor are often fraught with hazards. For example, can-
cer stem cell heterogeneity within a given tumor or class
of tumors can be manifested in their other properties,
and their identity can be confounded by the existence
of progenitor cell populations with extensive proliferative
capacity but not long term self-renewal potential, or the
presence in some tumors of a majority cell population
that is capable of both extensive long-term growth and
self-renewal. These possibilities need to be taken into
account in the experimental design and when deriving
conclusions from the results obtained. Heterogeneity in
tumor cell populations obtained from different patients
(or other sources) also mandates that sufficient sample
sizes be accrued and reported to support general
conclusions.
Take-Home Message
The field of cancer stem cells is an important one with great
opportunities for the generation of new understanding of
stem cell biology on a broad scale and clinical progress in
the cancer field. It is also clear that cancer stem cell biology
is amuchmore complex field thanwas envisagedwhen the
concept was initially introduced decades ago. We thus
remain very keen to receive and publish the wide range
of studies that can inform any aspect of this topic in a
significant and rigorous way without proscribing strict
guidelines as to what these must include. We trust this
Commentary will serve as a useful guide to the principles
we seek to adhere to in evaluating the strength of research
contributions to this exciting and dynamic area.
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